We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $9.59B
1-Year Est. Return 113.36%
This Fund
S&P 500
This Quarter Est. Return
+15.32%
1 Year Est. Return
+113.36%
3 Year Est. Return
+277.48%
5 Year Est. Return
+350.78%
10 Year Est. Return
+2,290.11%
AUM
$5.02B
AUM Growth
+$175M
Cap. Flow
-$1.93B
Cap. Flow %
-38.38%
Top 10 Hldgs %
37.55%
Holding
141
New
17
Increased
15
Reduced
22
Closed
12

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$70.1M
2
CPRX
Catalyst Pharmaceutical
CPRX
+$58M
3
RVMD icon
Revolution Medicines
RVMD
+$44M
4
LRMR icon
Larimar Therapeutics
LRMR
+$27.8M
5
VERV
Verve Therapeutics
VERV
+$23.9M

Top Sells

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$98.4M
2
AHCO icon
AdaptHealth
AHCO
+$60.2M
3
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$59M
4
GKOS icon
Glaukos
GKOS
+$53.6M
5
DAWN
Day One Biopharmaceuticals
DAWN
+$52.7M

Sector Composition

Rank Sector Weight
1 Healthcare 54.94%
2 Miscellaneous 43.71%
3 Financials 1.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVL
1
DELISTED
Nuvalent
NUVL
$376M 7.48%
19,341,024
– –
NBIX icon
2
Neurocrine Biosciences
NBIX
$16.1B
$161M 3.2%
1,512,714
-500,000
-25% -$50.7M
AHCO icon
3
AdaptHealth
AHCO
$856M
$154M 3.07%
8,223,536
-2,927,261
-26% -$60.2M
SILK
4
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$114M 2.27%
2,535,369
-141,522
-5% -$6.09M
CMAX
5
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$112M 2.24%
528,703
– –
GILD icon
6
Gilead Sciences
GILD
$188B
$94.9M 1.89%
1,537,539
-15,100
-1% -$952K
VTRS icon
7
Viatris
VTRS
$19.5B
$90.9M 1.81%
10,673,700
-10,000,000
-48% -$98.4M
BIIB icon
8
Biogen
BIIB
$33.2B
$88.1M 1.75%
+330,000
New +$70.1M
ISEE
9
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$76.1M 1.52%
4,244,098
-969,902
-19% -$12.7M
AERI
10
DELISTED
Aerie Pharmaceuticals
AERI
$73.5M 1.46%
4,855,005
+159,985
+3% +$1.86M
IMGN
11
DELISTED
Immunogen Inc
IMGN
$65.7M 1.31%
13,740,205
-1,280,285
-9% -$6.75M
CPRX
12
DELISTED
Catalyst Pharmaceutical
CPRX
$62.8M 1.25%
+4,896,000
New +$58M
LUNG icon
13
Pulmonx
LUNG
$97.1M
$62M 1.23%
3,720,901
+255,000
+7% +$4.7M
RVMD icon
14
Revolution Medicines
RVMD
$45.2B
$57M 1.14%
2,891,587
+2,000,000
+224% +$44M
LRMR icon
15
Larimar Therapeutics
LRMR
$398M
$54.2M 1.08%
16,941,357
+11,111,108
+191% +$27.8M
MRUS
16
DELISTED
Merus
MRUS
$50.5M 1.01%
2,521,553
+535,629
+27% +$12.8M
DCPH
17
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$46.1M 0.92%
2,491,490
-3,759,474
-60% -$59M
HLVX
18
DELISTED
HilleVax
HLVX
$45.3M 0.9%
2,653,231
+35,283
+1% +$513K
COGT icon
19
Cogent Biosciences
COGT
$6.06B
$44.3M 0.88%
2,966,345
-2,910,460
-50% -$39.9M
EOLS icon
20
Evolus
EOLS
$598M
$43.4M 0.86%
5,390,103
+1,757,352
+48% +$18.6M
MIRM icon
21
Mirum Pharmaceuticals
MIRM
$6.14B
$42.7M 0.85%
2,032,335
-1,212,099
-37% -$29.2M
CYTK icon
22
Cytokinetics
CYTK
$10.3B
$39.4M 0.78%
813,112
-347,203
-30% -$16.7M
EWTX icon
23
Edgewise Therapeutics
EWTX
$4.56B
$38.7M 0.77%
3,933,137
– –
ANAB icon
24
AnaptysBio
ANAB
$1.7B
$37.4M 0.74%
1,466,600
+694,600
+90% +$16.3M
BKD icon
25
Brookdale Senior Living
BKD
$2.85B
$37.1M 0.74%
8,692,561
+100,100
+1% +$474K
1
2 3 4 5

Similar funds

OAM
Oppenheimer Asset Management New York $9.63B AUM 30.32% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
MSE
MUFG Securities EMEA London, United Kingdom $9.53B AUM 52.96% 1-Year Est. Return
VF
Vest Financial Mclean, Virginia $9.52B AUM 31.6% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
A
Allianz Munich, Germany $9.48B AUM 23.58% 1-Year Est. Return
Edgewood Management
Edgewood Management Greenwich, Connecticut $9.69B AUM 6.52% 1-Year Est. Return

Deerfield Management's Q3 2022 Portfolio in Review

As of Q3 2022, Deerfield Management held 141 positions worth $5.02B, up 3.6% from $4.85B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Deerfield Management withdrew a net $1.93B in Q3 2022, closing 12 positions and reducing 22 holdings. Its most notable exit was Glaukos, an estimated $53.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, up from 52% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Deerfield Management opened a new position in Biogen worth $88.1M.

  • Deerfield Management's largest Q3 2022 buy was Biogen: 330,000 shares worth $88.1M.
  • Deerfield Management added most to Revolution Medicines in Q3 2022, an estimated $44M increase.
  • Deerfield Management's biggest Q3 2022 reduction was Viatris, cutting an estimated $98.4M.
  • Deerfield Management fully exited Glaukos in Q3 2022, selling an estimated $53.6M.
  • Deerfield Management's ten largest holdings make up 38% of its $5.02B portfolio in Q3 2022.
  • Deerfield Management opened 17 new positions and closed 12 in Q3 2022.
  • Deerfield Management's portfolio value rose 3.6% quarter-over-quarter to $5.02B.

Based on Deerfield Management's 13F filing for Q3 2022, filed 14 Nov 2022.